A Phase II randomised placebo-controlled, double blind, multisite study of Acetazolamide versus placebo for management of cerebral oedema in recurrent and/or progressive High Grade Glioma requiring treatment with Dexamethasone – The ACED trial

See ANZCTR for full trial details >

 

Trial Summary:

The purpose of this clinical research study is to determine whether adding acetazolamide to dexamethasone improves patient outcome and lessens corticosteroid side-effects in patients with recurrent or progressive high grade glioma. This study will also describe the possible side effects of both dexamethasone and acetazolamide on your quality of life.

Supported By:

Perpetual via CBCF; Cancer Australia, COGNO, NHMRC CTC

Eligibility:

Recurrent and/or progressive HGG patients who require recommencement of dexamethasone or dose increase due to progressive raised ICP regardless of aetiology

Registration ID:

ACTRN12615001072505

Participation:

Australia

Australian Lead Group:

COGNO, NHMRC CTC

Status:

In Follow Up

Activation Date:

24/02/2016

Chairs:

Prof Meera Agar

Contact:

aced.study@sydney.edu.au